January 2021 PMID 33185990

Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure.

John R Teerlink, Rafael Diaz, G Michael Felker, John J V McMurray, Marco Metra, Scott D Solomon, Kirkwood F Adams, Inder Anand, Alexandra Arias-Mendoza, Tor Biering-Sørensen, Michael Böhm, Diana Bonderman, John G F Cleland, Ramon Corbalan, Maria G Crespo-Leiro

Full text PDF Download social card

Mentions

191

Peak: 72 in Nov 2020

across 5 sources since Nov 2020

Extended reach

622,457

potential audience

Total likes

508

Video views

11,339

Mentions per month

Nov 2020 – Mar 2024

Where it's discussed

X / Twitter158 posts
News20 articles
Facebook5 posts
YouTube4 videos
Blogs4 articles

AI synopsis

What people are saying

Several discussions highlight key findings from the trial, such as the mention of reduced incidences of heart failure events and cardiovascular deaths in patients treated with omecamtiv mecarbil compared to placebo. Posts frequently use terms like 'modest reduction' and express concern about the relatively small effect size, demonstrating a tone of cautious optimism mixed with skepticism. For instance, comments reflect on how these outcomes may or may not translate to significant improvements in patient care, using analytical language that indicates critical engagement rather than outright endorsement.

AgreementNeither agree nor disagree

The discussions show mixed feelings about the publication’s conclusions, with some skepticism towards the effectiveness of omecamtiv mecarbil, suggesting a lack of strong consensus.

InterestHigh interest

Many participants express a high level of curiosity, frequently engaging with specifics of the trial and its implications for heart failure treatment.

EngagementModerate engagement

While some users discuss the details of the trials and their outcomes, others show a more superficial grasp of the content, indicating varied levels of engagement.

ImpactModerate impact

Overall, there is a recognition of the potential impact on treatment, but concerns about the modest benefits are prevalent, resulting in a less enthusiastic perception.

Abstract in brief

Omecamtiv mecarbil, a cardiac myosin activator, was tested for improving heart function in patients with heart failure and a low ejection fraction.
A trial with 8,256 patients compared the effects of omecamtiv mecarbil against a placebo, measuring heart failure events, hospitalizations, or deaths from cardiovascular causes.
Results showed fewer primary outcome events and cardiovascular deaths in the omecamtiv mecarbil group compared to placebo, but no significant difference in related heart failure symptoms or ischemic events.

Read the full abstract

All mentions

Guidelines for Pharmacotherapy in Heart Failure Management

Learn about the optimal medication prescriptions for patients with HFrEF based on the 2021 ESC Guidelines. This video discusses vericiguat, a promising new medication shown to reduce cardiovascular events in high-risk…

CardioMinds, Dr. Sherif Altoukhy · Jun 12, 2022 9,384 views

Optimizing Pharmacotherapy for Heart Failure with Reduced Ejection Fraction

This video explores the optimal medication strategies for patients with heart failure and reduced ejection fraction, in accordance with the 2021 ESC Guidelines. It examines the efficacy of new treatments, including…

CardioMinds, Dr. Sherif Altoukhy · Jun 11, 2022 1,920 views

June 3, 2022 This Week in Cardiology Podcast

Medscape · Mar 27, 2024 18 views

Dec 16, 2022 This Week in Cardiology Podcast

Medscape · Mar 27, 2024 17 views

kati manoto

@katimanoto · X

Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure | NEJM https://t.co/cPivaUpjFu

Dec 12, 2023 · 385 followers View post →

christymaginn

@christymaginn · X

@Biohazard3737 Because no one can tell why, what, how and when their products would be used if approved. Their website is hard to understand - you literally have to get to the first paragraph of the NEJM to get the real headline - heart failure. https://t.co/N8NSWbybpZ

Dec 6, 2023 · 2,326 followers View post →

Faby G.

@Fabiolaghh · X

RT @EduardoPerna1: @IccResidencia @jorge_thierer No es todo lo mismo Viejos Inotropicos=Calciotrópicos (actuan sobre Ca) Mitotrópicos (sobr…

May 31, 2023 · 1 share · 410 followers View post →

nekonekoz

@nekonekoz · X

https://t.co/ecU0Ms88eP

Mar 1, 2023 · 806 followers View post →

Professor M Z Khalil

@mzkhalil · X

Adding Omecamtiv Mecarbil to the big list of medications for HFrEF is not appreciated by patients. Perhaps a polypill strategy for HFrEF should be considered. https://t.co/wLSh2qiBDg https://t.co/6wMKqhHZXH

Feb 17, 2023 · 2,856 followers View post →

John Rickert

@JohnRickertMHIF · X

RT @thePagerNews: FDA advisory panel votes

Dec 21, 2022 · 1 share · 185 followers View post →

Academic Heart

@AcademicHeart · X

FDA advisory panel votes

Dec 21, 2022 · 1 like · 1 share · 1,076 followers View post →

Sam Straw

@DrSamStraw · X

RT @drjohnm: Drug is Omecamtiv Mecarbil Trial Galactic HF -- no change in CV death https://t.co/SDuHPq5V0M See Also METEROIC -- no chang…

Dec 14, 2022 · 2 shares · 617 followers View post →

Zach Brennan

@ZacharyBrennan · X

RT @drjohnm: Drug is Omecamtiv Mecarbil Trial Galactic HF -- no change in CV death https://t.co/SDuHPq5V0M See Also METEROIC -- no chang…

Dec 14, 2022 · 2 shares · 10,780 followers View post →

John Mandrola, MD

@drjohnm · X

Drug is Omecamtiv Mecarbil Trial Galactic HF -- no change in CV death https://t.co/SDuHPq5V0M See Also METEROIC -- no change in exercise time https://t.co/yAXfalewP4 I disc on #TWICPodcast https://t.co/qnREEZIO8c Surprising that it got 3 votes #CardioTwitter https://t.co/kv6oysYapQ

Dec 14, 2022 · 8 likes · 2 shares · 68,519 followers View post →

Passionate Davita

@PassionateDavi1 · X

RT @megikaya: 心筋ミオシン活性薬、オメカムチブという新しい心不全治療法の報告。NEJM HFrEF8200人のRCTでHR 0.92, p=0.03. 結論として有意に心不全イベント抑制した、というのは正しい解釈。ガイドラインも変わりそう。でもフォロー3年で…

Aug 18, 2022 · 1 share · 73 followers View post →

Alfred C. Chin

@alfredcchin · X

Myosin modulators target the mechanics of myosin-actin cross-bridge cycles. Key phase III trials show promising results for two myosin modulators: 1) Mavacamten @TheLancet 2020: https://t.co/DG1tY2W30r 2) Omecamtiv mecarbil @NEJM 2021: https://t.co/jLsZnvl2lt https://t.co/8BE9nLbc8x

Dec 13, 2021 · 1 like · 412 followers View post →

Manuel Abeytua

@AbeytuaManuel · X

RT @JuliaSellerm:

Dec 9, 2021 · 2 shares · 618 followers View post →

Juan Carlos Obaya

@jcobaya69 · X

RT @JuliaSellerm:

Dec 8, 2021 · 2 shares · 857 followers View post →

Julia Seller

@JuliaSellerm · X

Dec 8, 2021 · 14 likes · 2 shares · 6,012 followers View post →

Dr. Afzal Haq Asif

@Dr_AfzalHaqAsif · X

Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure | NEJM: Those who received omecamtiv mecarbil had a lower risk of a composite of heart-failure events and cardiovascular death than those who received placebo. https://t.co/2EnARL7kOJ

Oct 24, 2021 · 1 like · 746 followers View post →

Juan E Correa-Morales

@veladconmigo · X

Daily recommendation: GALACTIC HF trial Omecamtiv a new inotrope for HFrEF reduced a composite endpoint of hospitalizations and mortality. Also improve quality of life. #hpm https://t.co/vhztdIYGwP

Aug 12, 2021 · 871 followers View post →

猫になりたい薬剤師

@Vannyamoto · X

Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure https://t.co/axzFaVc7Xa 選択的心筋ミオシン活性化剤であるオメカムチブ・メカルビルのRCT

Jul 31, 2021 · 1,042 followers View post →

江花有亮 Yusuke Ebana MD PhD CReP

@ebnysk1 · X

心筋のミオシン活性化薬によって心不全・心血管死のイベントを低下。 Cardiac Myosin Activation with #OmecamtivMecarbil in Systolic Heart Failure | NEJM https://t.co/dRrMDfhQ0A

May 20, 2021 · 141 followers View post →

Nathan Johnstone

@njohnstone10 · X

No medications that directly enhance systolic function have improved outcomes in patients with #HFrEF Omecamtiv mecarbil, a new cardiac myosin activator, ⬆️ cardiac contractility and ⬇️ #heartfailure and sudden death. #biom4180 https://t.co/U11R67hsHO

Mar 27, 2021 · 1 like · 50 followers View post →

Serv. Farmacia CHUAC

@FarmaCHUAC · X

Omecamtiv Mecarbil en Insuficiencia Cardíaca con FE reducida:

Mar 19, 2021 · 2,254 followers View post →

Humberto Blanco

@humbertoblancoj · X

RT @JuliaSellerm: Top3 heart failure trials in January2021:

Feb 19, 2021 · 42 shares · 185 followers View post →

Adams CardioMD

@AdamsCardioMD · X

Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure | NEJM GALACTIC-HF https://t.co/9pEkcXzgTC

Feb 6, 2021 · 607 followers View post →

Nikita McKnight

@mcknight_nikita · X

In #BIOM4180 we recently discussed a new potential therapy for systolic heart failure patients, omecamtiv mecarbil, which is a myosin activator! It helps to increase heart contractility and only targets cardiac myocytes. Check out this Jan 2021 article! https://t.co/qWk6UmTsqX

Feb 5, 2021 · 80 followers View post →

Picchio Diego Huberto

@DiegoPicchio · X

RT @JuliaSellerm: Top3 heart failure trials in January2021:

Feb 1, 2021 · 42 shares · 631 followers View post →

Arturo J. Uscanga Padrón

@Arthu_uscanga · X

RT @JuliaSellerm: Top3 heart failure trials in January2021:

Jan 29, 2021 · 42 shares · 263 followers View post →

Lucrecia M. Burgos, MD

@lucreciamburgos · X

RT @JuliaSellerm: Top3 heart failure trials in January2021:

Jan 28, 2021 · 42 shares · 6,586 followers View post →

Albert Massó van Roessel

@amassovr · X

RT @JuliaSellerm: Top3 heart failure trials in January2021:

Jan 28, 2021 · 42 shares · 167 followers View post →

JóvenesSEC

@JovenesSec · X

RT @JuliaSellerm: Top3 heart failure trials in January2021:

Jan 28, 2021 · 42 shares · 5,994 followers View post →

saugat das gupta

@nephro_sdg · X

RT @JuliaSellerm: Top3 heart failure trials in January2021:

Jan 28, 2021 · 42 shares · 174 followers View post →

Alexandra Harris

@PharmDocHarris · X

@mikerograms https://t.co/3tpmwGRJHq

Jan 28, 2021 View post →

Ivan Mendoza

@mencardio · X

RT @JuliaSellerm: Top3 heart failure trials in January2021:

Jan 28, 2021 · 42 shares · 7,257 followers View post →

Miguel Turégano

@tureyedro · X

RT @JuliaSellerm: Top3 heart failure trials in January2021:

Jan 28, 2021 · 42 shares · 811 followers View post →

Alfa

@AlfasaurioAlfa · X

RT @JuliaSellerm: Top3 heart failure trials in January2021:

Jan 28, 2021 · 42 shares · 326 followers View post →

Valva Mitralis

@Mitrovalvology · X

RT @JuliaSellerm: Top3 heart failure trials in January2021:

Jan 28, 2021 · 42 shares · 4,135 followers View post →

Daniel Velarde

@dvelarde85 · X

RT @JuliaSellerm: Top3 heart failure trials in January2021:

Jan 28, 2021 · 42 shares · 612 followers View post →

Z. Dindane

@ZouDindaneMD · X

RT @JuliaSellerm: Top3 heart failure trials in January2021:

Jan 28, 2021 · 42 shares · 483 followers View post →

Osama Bisht

@Obisht · X

RT @JuliaSellerm: Top3 heart failure trials in January2021:

Jan 28, 2021 · 42 shares · 6,414 followers View post →

alfonso piñana lopez

@AlfonsoPinanaMF · X

RT @JuliaSellerm: Top3 heart failure trials in January2021:

Jan 28, 2021 · 42 shares · 475 followers View post →

David Lugo

@DHL23 · X

RT @JuliaSellerm: Top3 heart failure trials in January2021:

Jan 27, 2021 · 42 shares · 141 followers View post →

Henry Gaviria

@henrygav5 · X

RT @JuliaSellerm: Top3 heart failure trials in January2021:

Jan 27, 2021 · 42 shares · 257 followers View post →

SGLT2inhibitor_lover

@Sglt2inhibitorL · X

RT @JuliaSellerm: Top3 heart failure trials in January2021:

Jan 27, 2021 · 42 shares · 1,216 followers View post →

Xiqiang Wang, MD

@Xiqiang2 · X

RT @JuliaSellerm: Top3 heart failure trials in January2021:

Jan 27, 2021 · 42 shares · 39 followers View post →

Carolina Ortiz

@Carol_O_C · X

RT @JuliaSellerm: Top3 heart failure trials in January2021:

Jan 27, 2021 · 42 shares · 2,759 followers View post →

Medtorek

@Medtorek · X

RT @JuliaSellerm: Top3 heart failure trials in January2021:

Jan 27, 2021 · 42 shares · 13,852 followers View post →

Nicolas Manito

@Dr_Manito · X

RT @JuliaSellerm: Top3 heart failure trials in January2021:

Jan 27, 2021 · 42 shares · 5,469 followers View post →

Oscar Tahuahua

@OscarTahuahua · X

RT @JuliaSellerm: Top3 heart failure trials in January2021:

Jan 27, 2021 · 42 shares · 1,290 followers View post →

Alex Cristancho

@Dr_alexcr · X

RT @JuliaSellerm: Top3 heart failure trials in January2021:

Jan 27, 2021 · 42 shares · 251 followers View post →

Oswaldo Enrique Aguilar Molina MD

@AguilarMolina_ · X

RT @JuliaSellerm: Top3 heart failure trials in January2021:

Jan 27, 2021 · 42 shares · 370 followers View post →

LUIS GARCIA CARRION

@LGARCIALSM · X

RT @JuliaSellerm: Top3 heart failure trials in January2021:

Jan 27, 2021 · 42 shares · 484 followers View post →

SVCardio

@SVCardio · X

RT @JuliaSellerm: Top3 heart failure trials in January2021:

Jan 27, 2021 · 42 shares · 5,013 followers View post →

Edgardo Alania

@Ed_Alania · X

RT @JuliaSellerm: Top3 heart failure trials in January2021:

Jan 27, 2021 · 42 shares · 10,238 followers View post →

Miguel Azañedo V

@MikeMD2486 · X

RT @JuliaSellerm: Top3 heart failure trials in January2021:

Jan 27, 2021 · 42 shares · 404 followers View post →

Javier Torres

@JTLLERGO · X

RT @JuliaSellerm: Top3 heart failure trials in January2021:

Jan 27, 2021 · 42 shares · 5,163 followers View post →

Shelley Zieroth

@ShelleyZieroth · X

RT @JuliaSellerm: Top3 heart failure trials in January2021:

Jan 27, 2021 · 42 shares · 9,996 followers View post →

Chema Fernandez

@chemachir · X

RT @JuliaSellerm: Top3 heart failure trials in January2021:

Jan 27, 2021 · 42 shares · 3,836 followers View post →

Bohdan Khomtchouk, Ph.D.

@bohdanome · X

RT @JuliaSellerm: Top3 heart failure trials in January2021:

Jan 27, 2021 · 42 shares · 322 followers View post →

Dr.Félix09Rodríguez

@PhellixR · X

RT @JuliaSellerm: Top3 heart failure trials in January2021:

Jan 27, 2021 · 42 shares · 1,354 followers View post →

Umut Kocabaş

@UmutKocabasMD · X

RT @JuliaSellerm: Top3 heart failure trials in January2021:

Jan 27, 2021 · 42 shares · 1,459 followers View post →

Paola Morejón Barragán

@paomorejon · X

RT @JuliaSellerm: Top3 heart failure trials in January2021:

Jan 27, 2021 · 42 shares · 18,410 followers View post →

Alfonso Valle

@ValleAlfonso · X

RT @JuliaSellerm: Top3 heart failure trials in January2021:

Jan 27, 2021 · 42 shares · 21,711 followers View post →

Gonzalo L Alonso Salinas

@Gontxi7 · X

RT @JuliaSellerm: Top3 heart failure trials in January2021:

Jan 27, 2021 · 42 shares · 1,610 followers View post →

Julia Seller

@JuliaSellerm · X

Top3 heart failure trials in January2021:

Jan 27, 2021 · 114 likes · 42 shares · 6,012 followers View post →

Paracelsus Pharmacology

@PMUpharmacology · X

Cardiac myosin activator omecamtiv mecarbil shows modest risk reduction of first heart failure event / cardiovascular death composite in patients with systolic heart failure, GALACTIC-HF trial suggests: https://t.co/825cBG3a9T

Jan 25, 2021 · 2 likes · 36 followers View post →

SC Farmàcia Clínica

@SCFarmClin · X

RT @Sefap_FAP: (NYJM) Omecamtiv mecarbil en insuficiencia cardíaca https://t.co/5TAe8buJWr

Jan 22, 2021 · 1 share · 1,674 followers View post →

Jeremy S. Pollock

@bmorecardiology · X

#Clinicalquestion Will there be a place for Omecamtiv Mecarbil in the HF armamentarium? If so, for whom and when? @gcfmd @MKIttlesonMD @ATRIUMRx @tonkhueMdPhd @GRamaniMD @NEJM @HFSA https://t.co/9QAySfw3Qq

Jan 19, 2021 · 2 likes · 1,620 followers View post →

SEFAP

@Sefap_FAP · X

(NYJM) Omecamtiv mecarbil en insuficiencia cardíaca https://t.co/5TAe8buJWr

Jan 19, 2021 · 1 share · 7,952 followers View post →

Last Week in Medicine

@lastweekinmed · X

Among patients with heart failure and a reduced ejection, those who received omecamtiv mecarbil had a lower incidence of a composite of a heart-failure event or death from cardiovascular causes than those who received placebo. @NEJM #heartfailure https://t.co/VR8rRSCn2b

Jan 17, 2021 · 1 like · 866 followers View post →

McGreevyMD

@McGreevyMD · X

Omecantiv decreased hospitalizations in HFrEF. The effect was modest (HR of .92). Says it decreased mortality as well - but the numbers don't add up to me. #medicine #Cardiology #news #medical #residency https://t.co/ED7tLsDW1t

Jan 17, 2021 · 116 followers View post →

Mushfiquzzaman

@Mushfiq_16 · X

Among patients with heart failure and a reduced ejection, those who received omecamtiv mecarbil (previously "CK-1827452") had a lower incidence of a composite of a heart-failure event or death from cardiovascular causes than those who received placebo. https://t.co/Py3TaF1ZFQ

Jan 17, 2021 · 166 followers View post →

Sandip Ghimire

@DrSandipGhimire · X

Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure | NEJM|GALACTIC-HF Trial https://t.co/6CZEkXgtx8

Jan 16, 2021 · 3 likes · 1,566 followers View post →

Jose Daniel Mosquera Lozano

@jdmosqueral · X

Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure | NEJM https://t.co/vFRfzNfxEu

Jan 16, 2021 · 232 followers View post →

Asociación Enfermos Displasia Arritmogénica DAVD

@asociaciondavd · X

RT @EduZatarain:

Jan 16, 2021 · 2 shares · 233 followers View post →

j kalet g pereyra

@kaletpereyra · X

RT @ValleAlfonso: @NEJM

Jan 14, 2021 · 1 share · 185 followers View post →

Alfonso Valle

@ValleAlfonso · X

@NEJM

Jan 14, 2021 · 3 likes · 1 share · 21,711 followers View post →

Ryo Horita, MD.

@hrt01a · X

RT @Susumu_Manabe: 心ミオシン活性化薬Omecamtiv Mecarbilが駆出率の低下した症候性心不全患者の心臓イベント（心臓死または心不全による入院または救急受診）を有意に抑制する．大規模二重盲検無作為化比較試験の結果https://t.co/rHN60…

Jan 14, 2021 · 1 share · 1,436 followers View post →

真鍋晋@心臓外科医

@Susumu_Manabe · X

Jan 14, 2021 · 14 likes · 1 share · 2,311 followers View post →

john morley

@drjohnmorley · X

Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure | NEJM https://t.co/r1JCPFmTiD

Jan 14, 2021 · 8,322 followers View post →

Grupo Investigación Multidisciplinar Extremeño

@GRIMEX_ · X

Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure | NEJM https://t.co/25UYNdMMEZ

Jan 14, 2021 · 361 followers View post →

@investigando

@rocatanho · X

Los pacientes con insuficiencia cardíaca sistólica y fracción reducida que reciben omecamtiv tendrían una menor incidencia de insuficiencia cardíaca o muertes por causas CV https://t.co/Dvqcs6iJww

Jan 14, 2021 · 400 followers View post →

Abdallah Al-Mohammad

@AAlMohammad87 · X

#GALACTIC_HF @NEJM omecamtiv mecarbil in pts with #HFrEF lowered incidence of a composite of a HF event or CV death; vs placebo [HR 0.92, strong enough?]. No differences in mortality or in #KCCQ score. @BSHeartFailure @ProfMartinCowie @markcpetrie20 DOI: 10.1056/NEJMoa2025797

Jan 14, 2021 · 1 like · 926 followers View post →

Zorba Blázquez Bermejo

@ZorbaBlazquez · X

RT @EduZatarain:

Jan 14, 2021 · 2 shares · 1,140 followers View post →

Moises Jimenez

@moisesjimenezs · X

Cardiac Myosin Activators and HFrEF https://t.co/v2VSP8qNUi

Jan 13, 2021 · 1,994 followers View post →

Juan Senior

@jsenior64 · X

https://t.co/e0ggxOGlhi

Jan 13, 2021 · 11,063 followers View post →

加藤隆寛

@tak_pharmacist · X

ミオシン活性化薬の臨床試験GALACTIC-HFの結果。期待されたほどのアウトカムは示せなかったと言われていますが、個人的には、利尿をかけるとLOSになってしまって手詰まり感のある超低心機能での選択肢が増えるのではと期待。#心不全 #ミオシン活性化 #新薬　 https://t.co/Ym8x4ItmnO

Dec 25, 2020 · 1 like · 401 followers View post →

Masahiro Nakashima｜シンリハタロウ｜心リハの敷居をそっと低くするひと

@shinrihataro · X

HFrEF（EF≦35%）における心筋ミオシン活性化薬（Omecamtiv Mecarbil）の予後改善効果に関する対プラセボRCTの報告。効果は限定的なようですがこれをどう考えるべきなんでしょうか。 Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure | NEJM https://t.co/M43ApF0KAx

Dec 14, 2020 · 2,419 followers View post →

Eduardo Perna

@EduardoPerna1 · X

@IccResidencia @jorge_thierer No es todo lo mismo Viejos Inotropicos=Calciotrópicos (actuan sobre Ca) Mitotrópicos (sobre la energética) Miotrópicos (sobre el sarcómero)=OM⬇️ hospitalización por IC o muerte CV 8%. Leer: https://t.co/01K9M3TZ36 https://t.co/cAiRauywuQ https://t.co/rH7xki4xAE

Nov 27, 2020 · 3 likes · 1 share · 1,912 followers View post →

pinacol

@pinacol · X

【RCT】駆出率が35%以下の症候性慢性心不全患者へのオメカムチブメカルビル投与は、プラセボ投与と比較して、主要評価項目（最初の心不全イベント（心不全による入院や緊急の受診）または心血管死）を減少させた。 #ペ読 https://t.co/QSOFeW8XMC

Nov 22, 2020 · 1,616 followers View post →

Quini

@DrQuini · X

https://t.co/4KiH8ng4LA

Nov 22, 2020 · 1,218 followers View post →

バン@内科医のジレンマ

@lostphysicianYB · X

オメカムチブ・メカルビルは１次アウトカム(心不全・心血管系死亡)イベントをごくわずか(HR=0.92;95%CI 0.86-0.99)減らしたのみ。面白い薬ではあるけども。 https://t.co/dVjJcSSFXH

Nov 22, 2020 · 4,334 followers View post →

Geriatric Registrar

@GerisReg · X

Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure | NEJM https://t.co/W4njWnNAkS

Nov 19, 2020 · 1,375 followers View post →

Cardiology

@PracUpCardio · X

Cardiac Myosin Activation With Omecamtiv Mecarbil in Systolic Heart Failure https://t.co/3VxqFJiOfI #cardiology

Nov 19, 2020 · 884 followers View post →

@investigando

@rocatanho · X

Pac c/insuficiencia cardíaca y fracción de eyección reducida que reciben el activador selectivo de miosina cardíaca omecamtiv mecarbil tendrían una menor incidencia de insuficiencia cardíaca o muerte por causas cardiovasculares que los que reciben placebo https://t.co/wKUfpa0d9X

Nov 18, 2020 · 400 followers View post →

the paper link

@the_paper_link · X

Trend new: **Teerlink JR** et al (N Engl J Med) __Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure__ https://t.co/UKL3aoiBSL

Nov 17, 2020 · 136 followers View post →

Sean Ninan

@sean9n · X

New heart failure medication. https://t.co/1N7yK7SCNC

Nov 17, 2020 · 4,336 followers View post →

Elvis Amao Ruiz

@elvisjar · X

Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure | NEJM https://t.co/2atMzXoHaz

Nov 17, 2020 · 253 followers View post →

官澤洋平 YK Hospitalist

@Yohei_Kanzawa · X

オメカムティヴマカビル。 Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure | NEJM https://t.co/W1ppSfQG7g

Nov 17, 2020 · 1 like · 3,214 followers View post →

David Warriner

@DrDavidWarriner · X

RT @AAlMohammad87: Results of #GALACTIC_HF trial @NEJM: reduced composite of HF event and CV death amongst patients with HFrEF treated with…

Nov 17, 2020 · 1 share · 7,271 followers View post →

Farmacia Madrid AP

@FarmaMadridAP · X

(NEJM) Activación de miosina cardíaca con Omecamtiv Mecarbil en insuficiencia cardíaca sistólica https://t.co/nVjPxrVQVb https://t.co/bzhLhfvByi

Nov 17, 2020 · 8,361 followers View post →

Abdallah Al-Mohammad

@AAlMohammad87 · X

Results of #GALACTIC_HF trial @NEJM: reduced composite of HF event and CV death amongst patients with HFrEF treated with Omecamtive Mecarbil, with a HR of 0.92, a small margin of improvement @BSHeartFailure @scottdsolomon @markcpetrie20 @DrDavidWarriner DOI: 10.1056/NEJMoa2025797

Nov 17, 2020 · 1 share · 926 followers View post →

UKCPA Heart Failure sub-Committee

@ukcpahf · X

RT @BSHeartFailure: GALACTIC-HF published: modest reduction (HR 0.92) in first heart-failure event or CV death among 8256 patients (LVEF 27…

Nov 17, 2020 · 1 share · 432 followers View post →

Francesc Formiga

@FormigaFrancesc · X

Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure | NEJM https://t.co/hYOQIRIaIE

Nov 17, 2020 · 1,947 followers View post →

renalRCTs

@renalRCTs · X

Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure. https://t.co/7GO27nZtDv https://t.co/rVjEIOiZCC

Nov 16, 2020 · 39 followers View post →

Gerardo Zavala García

@ZavalaGerard · X

RT @paomorejon: El estudio que todo especialista en #InsuficienciaCardiaca esperaba

Nov 15, 2020 · 30 shares · 476 followers View post →

Mario Suárez

@Mariosm148 · X

RT @paomorejon: El estudio que todo especialista en #InsuficienciaCardiaca esperaba

Nov 14, 2020 · 30 shares · 70 followers View post →

Rajinder

@Rajinder · X

RT @ALEX_MISCHIE: Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure @NEJM @AHAMeetings https://t.co/iOVmfjf4Ps…

Nov 14, 2020 · 3 shares · 770 followers View post →

Eduardo Enriquez

@EnriquezEdwardo · X

RT @paomorejon: El estudio que todo especialista en #InsuficienciaCardiaca esperaba

Nov 14, 2020 · 30 shares · 760 followers View post →

Daniel J Drucker

@DanielJDrucker · X

How to Assess the Magnitude of Innovation #Heartfailure Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure https://t.co/GzgmVyHMC0

Nov 14, 2020 · 34,194 followers View post →

Sultania Cardiovascular Sciences

@SultaniaCardio1 · X

RT @mvaduganathan: Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure Landmark #GALACTICHF trial late-breaking pr…

Nov 14, 2020 · 14 shares · 296 followers View post →

Nuria Martínez

@NuryMLopez · X

RT @paomorejon: El estudio que todo especialista en #InsuficienciaCardiaca esperaba

Nov 14, 2020 · 30 shares · 43 followers View post →

Carlos Ortiz Bautista

@Carlos_Ortiz85 · X

RT @paomorejon: El estudio que todo especialista en #InsuficienciaCardiaca esperaba

Nov 14, 2020 · 30 shares · 513 followers View post →

| Daniel Sierra LM |

@DanielSierraLM · X

RT @paomorejon: El estudio que todo especialista en #InsuficienciaCardiaca esperaba

Nov 14, 2020 · 30 shares · 2,499 followers View post →

Belén

@bezadii · X

RT @paomorejon: El estudio que todo especialista en #InsuficienciaCardiaca esperaba

Nov 13, 2020 · 30 shares · 272 followers View post →

Jose Rubio Escolar

@prubioe · X

RT @paomorejon: El estudio que todo especialista en #InsuficienciaCardiaca esperaba

Nov 13, 2020 · 30 shares · 24 followers View post →

Josué Félix Córdova

@Noinvasivo · X

RT @paomorejon: El estudio que todo especialista en #InsuficienciaCardiaca esperaba

Nov 13, 2020 · 30 shares · 35 followers View post →

gustavo rojas lara

@gmdc1958 · X

RT @paomorejon: El estudio que todo especialista en #InsuficienciaCardiaca esperaba

Nov 13, 2020 · 30 shares · 998 followers View post →

Olly Brown

@OllyBrown · X

RT @UoGHeartFailure: Online now in @NEJM - Results of GALACTIC-HF Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Fail…

Nov 13, 2020 · 3 shares · 435 followers View post →

ツ Jorge Castro ツ

@Jorgito_Kstro · X

RT @paomorejon: El estudio que todo especialista en #InsuficienciaCardiaca esperaba

Nov 13, 2020 · 30 shares · 480 followers View post →

Mimi_ Cardio

@mimi_cardio · X

RT @mvaduganathan: Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure Landmark #GALACTICHF trial late-breaking pr…

Nov 13, 2020 · 14 shares · 188 followers View post →

José Llumiquinga Mar

@etsajose · X

RT @paomorejon: El estudio que todo especialista en #InsuficienciaCardiaca esperaba

Nov 13, 2020 · 30 shares · 191 followers View post →

Ken Ejiri, MD, PhD 江尻健太郎

@KenEjiri · X

Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure | NEJM https://t.co/hEpdV1kK2i

Nov 13, 2020 · 431 followers View post →

Dr. Diógenes el Ansioso

@DrDiogenesxxx · X

RT @paomorejon: El estudio que todo especialista en #InsuficienciaCardiaca esperaba

Nov 13, 2020 · 30 shares · 14,258 followers View post →

Piedad Gonzalez Ferreira

@piedad_gonzale · X

RT @paomorejon: El estudio que todo especialista en #InsuficienciaCardiaca esperaba

Nov 13, 2020 · 30 shares · 27 followers View post →

juan lopez

@jd1lopez · X

RT @paomorejon: El estudio que todo especialista en #InsuficienciaCardiaca esperaba

Nov 13, 2020 · 30 shares · 1,074 followers View post →

Mauricio Rojas

@MauricioRojas95 · X

RT @paomorejon: El estudio que todo especialista en #InsuficienciaCardiaca esperaba

Nov 13, 2020 · 30 shares · 399 followers View post →

Ramon Bascompte

@RamonBascompte · X

RT @paomorejon: El estudio que todo especialista en #InsuficienciaCardiaca esperaba

Nov 13, 2020 · 30 shares · 327 followers View post →

PyMarketWatch

@PyMarketWatch · X

Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure - https://t.co/5ONaKUpd5u https://t.co/pn44EdPCRB

Nov 13, 2020 · 349 followers View post →

Peter Lüdike

@luedike · X

Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure | NEJM ....another „brick in the wall“

Nov 13, 2020 · 1 like · 1,948 followers View post →

Dionicia Pizarnik Storni

@AleGalu24 · X

RT @paomorejon: El estudio que todo especialista en #InsuficienciaCardiaca esperaba

Nov 13, 2020 · 30 shares · 76 followers View post →

Alejandro I. Pérez Cabeza

@alejandroipc2 · X

RT @mvaduganathan: Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure Landmark #GALACTICHF trial late-breaking pr…

Nov 13, 2020 · 14 shares · 1,164 followers View post →

Ana Vergés

@VergesAna · X

RT @paomorejon: El estudio que todo especialista en #InsuficienciaCardiaca esperaba

Nov 13, 2020 · 30 shares · 424 followers View post →

ste-nurse

@liofilizado_ · X

RT @paomorejon: El estudio que todo especialista en #InsuficienciaCardiaca esperaba

Nov 13, 2020 · 30 shares · 162 followers View post →

Ramiro Esparza

@docramiro · X

RT @paomorejon: El estudio que todo especialista en #InsuficienciaCardiaca esperaba

Nov 13, 2020 · 30 shares · 68,310 followers View post →

Carolina Tiraplegui

@Carolina_tgel · X

RT @paomorejon: El estudio que todo especialista en #InsuficienciaCardiaca esperaba

Nov 13, 2020 · 30 shares · 380 followers View post →

DrBecher

@DrBeat019 · X

RT @paomorejon: El estudio que todo especialista en #InsuficienciaCardiaca esperaba

Nov 13, 2020 · 30 shares · 911 followers View post →

Paola Beltran Tronco

@paolabel_cardio · X

RT @paomorejon: El estudio que todo especialista en #InsuficienciaCardiaca esperaba

Nov 13, 2020 · 30 shares · 3,293 followers View post →

Melissa Rodriguez Israel

@meli_rod_israel · X

RT @paomorejon: El estudio que todo especialista en #InsuficienciaCardiaca esperaba

Nov 13, 2020 · 30 shares · 139 followers View post →

McMaster Heart Function Education

@MacHeartFailure · X

RT @mvaduganathan: Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure Landmark #GALACTICHF trial late-breaking pr…

Nov 13, 2020 · 14 shares · 509 followers View post →

Edgardo Alania

@Ed_Alania · X

RT @paomorejon: El estudio que todo especialista en #InsuficienciaCardiaca esperaba

Nov 13, 2020 · 30 shares · 10,238 followers View post →

Gustavo Cortez

@Gustavo22205004 · X

RT @paomorejon: El estudio que todo especialista en #InsuficienciaCardiaca esperaba

Nov 13, 2020 · 30 shares · 439 followers View post →

David Reina Hoyos

@davidreinah · X

RT @paomorejon: El estudio que todo especialista en #InsuficienciaCardiaca esperaba

Nov 13, 2020 · 30 shares · 183 followers View post →

Ahmed Mohsen

@drahmedmohsen85 · X

RT @ALEX_MISCHIE: Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure @NEJM @AHAMeetings https://t.co/iOVmfjf4Ps…

Nov 13, 2020 · 3 shares · 22,874 followers View post →

Usman Shah

@cardiacshah · X

RT @UoGHeartFailure: Online now in @NEJM - Results of GALACTIC-HF Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Fail…

Nov 13, 2020 · 3 shares · 381 followers View post →

Lena E. Trager, MD

@LenaETrager · X

RT @mvaduganathan: Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure Landmark #GALACTICHF trial late-breaking pr…

Nov 13, 2020 · 14 shares · 2,518 followers View post →

ALEXANDRU MISCHIE

@ALEX_MISCHIE · X

Nov 13, 2020 · 14 likes · 3 shares · 10,321 followers View post →

Paola Morejón Barragán

@paomorejon · X

El estudio que todo especialista en #InsuficienciaCardiaca esperaba

Nov 13, 2020 · 84 likes · 30 shares · 18,410 followers View post →

Professor Vijay Kunadian

@VijayKunadian · X

Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure | NEJM GALACTIC HF https://t.co/tF5KNqGjMk

Nov 13, 2020 · 5,051 followers View post →

OlgaDunaeva

@DunyaOlga · X

RT @mvaduganathan: Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure Landmark #GALACTICHF trial late-breaking pr…

Nov 13, 2020 · 14 shares · 190 followers View post →

Clyde Yancy, MD, MSc

@NMHheartdoc · X

RT @mvaduganathan: Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure Landmark #GALACTICHF trial late-breaking pr…

Nov 13, 2020 · 14 shares · 15,464 followers View post →

Najdat Bazarbashi نجدت بازارباشي

@NajdatB1 · X

RT @mvaduganathan: Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure Landmark #GALACTICHF trial late-breaking pr…

Nov 13, 2020 · 14 shares · 733 followers View post →

CardioInfo

@Cardioinfo_it · X

RT @mvaduganathan: Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure Landmark #GALACTICHF trial late-breaking pr…

Nov 13, 2020 · 14 shares · 9,219 followers View post →

jennybnp

@jhernandeznp · X

RT @mvaduganathan: Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure Landmark #GALACTICHF trial late-breaking pr…

Nov 13, 2020 · 14 shares · 607 followers View post →

Dr.Rajiv Sankaranarayanan

@DrRajivsankar · X

RT @mvaduganathan: Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure Landmark #GALACTICHF trial late-breaking pr…

Nov 13, 2020 · 14 shares · 3,980 followers View post →

Nikhil Narang, MD

@Nikhil15 · X

RT @mvaduganathan: Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure Landmark #GALACTICHF trial late-breaking pr…

Nov 13, 2020 · 14 shares · 3,057 followers View post →

Edward El-Am, MD

@EdwardElAmm · X

RT @mvaduganathan: Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure Landmark #GALACTICHF trial late-breaking pr…

Nov 13, 2020 · 14 shares · 531 followers View post →

Kieran Docherty

@Kieranfdocherty · X

RT @UoGHeartFailure: Online now in @NEJM - Results of GALACTIC-HF Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Fail…

Nov 13, 2020 · 3 shares · 764 followers View post →

University of Glasgow Heart Failure Research Group

@UoGHeartFailure · X

Online now in @NEJM - Results of GALACTIC-HF Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure https://t.co/OfX3qnj3bF

Nov 13, 2020 · 5 likes · 3 shares · 1,384 followers View post →

Muthu Vaduganathan

@mvaduganathan · X

Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure Landmark #GALACTICHF trial late-breaking presentation at #AHA20 now published in @NEJM https://t.co/77iORC902z

Nov 13, 2020 · 61 likes · 14 shares · 9,164 followers View post →

Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure.

Mentions per month

Where it's discussed

What people are saying

Abstract in brief

Top posts

All mentions

Guidelines for Pharmacotherapy in Heart Failure Management

Optimizing Pharmacotherapy for Heart Failure with Reduced Ejection Fraction

June 3, 2022 This Week in Cardiology Podcast

Dec 16, 2022 This Week in Cardiology Podcast